Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1

Journal of Clinical Virology

Volumn 52, Issue 2, 2011, Pages 70-78

  Renaud, Christian ^a,b,c   Kuypers, Jane ^a,b   Englund, Janet A ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

Diagnosis; Influenza; Oseltamivir resistant; Outcome; PCR; Treatment

Indexed keywords

HEMAGGLUTININ; OSELTAMIVIR; PERAMIVIR; SIALIC ACID; SIALIDASE; ZANAMIVIR;

DRUG RESISTANCE; GENOTYPE; HUMAN; IMMUNOCOMPETENCE; INFLUENZA VIRUS A H1N1; MIXED INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC FITNESS; GENOTYPE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PANDEMICS; PHENOTYPE; SEASONS;

EID: 80052770280     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.05.019     Document Type: Review

References (114)

1. Lee V.J., Yap J., Cook A.R., Chen M.I., Tay J.K., Tan B.H., et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. New Engl J Med 2010, 362(June (23)):2166-2174.
2. Sheu T.G., Deyde V.M., Okomo-Adhiambo M., Garten R.J., Xu X., Bright R.A., et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008, 52(September (9)):3284-3292.
3. WHO. Influenza A virus resistance to oseltamivir and other antiviral medicines. ; 2009. http://www.who.int/csr/disease/influenza/2008-9nhemisummaryreport/en/index.html.
4. Gamblin S.J., Skehel J.J. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010, 285(September (37)):28403-28409.
5. Bloom J.D., Gong L.I., Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010, 328(June (5983)):1272-1275.
6. Collins P.J., Haire L.F., Lin Y.P., Liu J., Russell R.J., Walker P.A., et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 2009, 27(October (45)):6317-6323.
7. Ferraris O., Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008, 41(January (1)):13-19.
8. Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 2000, 10(January-February (1)):45-55.
9. Aoki F.Y., Boivin G., Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007, 12(4):603-616.
10. Okomo-Adhiambo M., Nguyen H.T., Sleeman K., Sheu T.G., Deyde V.M., Garten R.J., et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antivir Res 2010, 85(February (2)):381-388.
11. Nguyen H.T., Sheu T.G., Mishin V.P., Klimov A.I., Gubareva L.V. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010, 54(9):3671-3677.
12. Deng Y.M., Caldwell N., Hurt A., Shaw T., Kelso A., Chidlow G., et al. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antivir Res 2011, 90(April (1)):87-91.
13. Deyde V.M., Gubareva L.V. Influenza genome analysis using pyrosequencing method: current applications for a moving target. Expert Rev Mol Diagn 2009, 9(July (5)):493-509.
14. Deyde V.M., Sheu T.G., Trujillo A.A., Okomo-Adhiambo M., Garten R., Klimov A.I., et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010, 54(March (3)):1102-1110.
15. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antivir Res 2009, 81(January (1)):16-24.
16. Lackenby A., Democratis J., Siqueira M.M., Zambon M.C. Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther 2008, 13(6):809-820.
17. Gibson N.J. The use of real-time PCR methods in DNA sequence variation analysis. Clin Chim Acta 2006, 363(January (1-2)):32-47.
18. Kim S., Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng 2007, 9:289-320.
19. Guo L., Garten R.J., Foust A.S., Sessions W.M., Okomo-Adhiambo M., Gubareva L.V., et al. Rapid identification of oseltamivir-resistant influenza A(H1N1) viruses with H274Y mutation by RT-PCR/restriction fragment length polymorphism assay. Antivir Res 2009, 82(April (1)):29-33.
20. Bolotin S., Robertson A.V., Eshaghi A., De Lima C., Lombos E., Chong-King E., et al. Development of a novel real-time reverse-transcriptase PCR method for the detection of H275Y positive influenza A H1N1 isolates. J Virol Methods 2009, 158(June (1-2)):190-194.
21. Liu C.M., Driebe E.M., Schupp J., Kelley E., Nguyen J.T., McSharry J.J., et al. Rapid quantification of single-nucleotide mutations in mixed influenza A viral populations using allele-specific mixture analysis. J Virol Methods 2010, 163(January (1)):109-115. 2010.
22. Carr M.J., Sayre N., Duffy M., Connell J., Hall W.W. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses. J Virol Methods 2008, 153(November (2)):257-262.
23. Hata M., Tanaka S., Yasui Y., Fujiwara N., Kobayashi S., Minagawa H. A rapid genotypic assay for the detection of oseltamivir-resistant influenza A (H1N1) viruses. J Clin Microbiol 2010, 48(5):1983-1984.
24. Ngai K.L., Lam W.Y., Lee N., Leung T.F., Hui D.S., Chan P.K. Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza a H1N1 (H275Y) oseltamivir-resistant and wild-type viruses. J Med Virol 2010, 82(August (8)):1295-1298.
25. Steain M.C., Dwyer D.E., Hurt A.C., Kol C., Saksena N.K., Cunningham A.L., et al. Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification. Antivir Res 2009, 84(December (3)):242-248.
26. Suzuki Y., Saito R., Sato I., Zaraket H., Nishikawa M., Tamura T., et al. Identification of oseltamivir resistance among pandemic and seasonal influenza A (H1N1) viruses by an His275Tyr genotyping assay using the cycling probe method. J Clin Microbiol 2010, 49(January (1)):125-130.
27. Chidlow G.R., Harnett G.B., Williams S.H., Tempone S.S., Speers D.J., Hurt A.C., et al. The detection of oseltamivir-resistant pandemic influenza A/H1N1 2009 viruses using a real-time RT-PCR assay. J Virol Methods 2010, 169(October (1)):47-51.
28. Wang B., Dwyer D.E., Blyth C.C., Soedjono M., Shi H., Kesson A., et al. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antivir Res 2010, 87(July (1)):16-21.
29. Hindiyeh M., Ram D., Mandelboim M., Meningher T., Hirsh S., Robinov J., et al. Rapid detection of influenza A pandemic (H1N1) 2009 virus neuraminidase resistance mutation H275Y by real-time RT-PCR. J Clin Microbiol 2010, 48(5):1884-1887.
30. Renaud C., Kuypers J., Corey L. Diagnostic accuracy of an allele-specific reverse transcriptase-PCR assay targeting the H275Y oseltamivir resistant mutation in 2009 pandemic influenza A/H1N1 virus. J Clin Virol 2010, 49(1):21-25.
31. van der Vries E., Jonges M., Herfst S., Maaskant J., Van der Linden A., Guldemeester J., et al. Evaluation of a rapid molecular algorithm for detection of pandemic influenza A (H1N1) 2009 virus and screening for a key oseltamivir resistance (H275Y) substitution in neuraminidase. J Clin Virol 2010, 47(January (1)):34-37.
32. Bennett S., Gunson R.N., MacLean A., Miller R., Carman W.F. The validation of a real-time RT-PCR assay which detects influenza A and types simultaneously for influenza A H1N1 (2009) and oseltamivir-resistant (H275Y) influenza A H1N1 (2009). J Virol Methods 2010, 171(January (1)):86-90.
33. Mahony J.B., Chong S., Luinstra K., Petrich A., Smieja M. Development of a novel bead-based multiplex PCR assay for combined subtyping and oseltamivir resistance genotyping (H275Y) of seasonal and pandemic H1N1 influenza A viruses. J Clin Virol 2010, 49(December (4)):277-282.
34. Nukiwa N., Suzuki A., Furuse Y., Shimabukuro K., Odagiri T., Khandaker I., et al. Simplified screening method for detecting oseltamivir resistant pandemic influenza A (H1N1) 2009 virus by a RT-PCR/restriction fragment length polymorphism assay. J Virol Methods 2010, 170(December (1-2)):165-168.
35. Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., Hayden F.G. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001, 183(February (4)):523-531.
36. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364(9436):759-765. [August 28-September 3].
37. Li C.C., Wang L., Eng H.L., You H.L., Chang L.S., Tang K.S., et al. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis 2010, 16(August (8)):1265-1272.
38. Ward P., Small I., Smith J., Suter P., Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005, 55(February (Suppl. 1)):i5-i21.
39. Stephenson I., Democratis J., Lackenby A., McNally T., Smith J., Pareek M., et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009, 48(February (4)):389-396.
40. Weinstock D.M., Gubareva L.V., Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. New Engl J Med 2003, 348(February (9)):867-868.
41. Ujike M., Shimabukuro K., Mochizuki K., Obuchi M., Kageyama T., Shirakura M., et al. Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg Infect Dis 2010, 16(June (6)):926-935.
42. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009, 15(February (2)):155-162.
43. Hauge S.H., Blix H.S., Borgen K., Hungnes O., Dudman S.G. Aavitsland P. Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Virol J 2009, 6:54.
44. Esposito S., Molteni C.G., Daleno C., Valzano A., Fossali E., Da Dalt L., et al. Clinical importance and impact on the households of oseltamivir-resistant seasonal A/H1N1 influenza virus in healthy children in Italy. Virol J 2010, 7:202.
45. Casalegno J.S., Bouscambert-Duchamp M., Caro V., Schuffenecker I., Sabatier M., Traversier A., et al. Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009. Antivir Res 2010, 87(2):242-248.
46. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301(March (10)):1034-1041.
47. Buchholz U., Brockmann S., Duwe S., Schweiger B., an der Heiden M., Reinhardt B., et al. Household transmissibility and other characteristics of seasonal oseltamivir-resistant influenza A(H1N1) viruses Germany, 2007-2008. Euro Surveill 2010, 15(February (6)).
48. Mossong J., Opp M., Gerloff N., Hau P., Kremer J., Lackenby A., et al. Emergence of oseltamivir-resistant influenza A H1N1 virus during the 2007-2008 winter season in Luxembourg: clinical characteristics and epidemiology. Antivir Res 2009, 84(October (1)):91-94.
49. Ciancio B.C., Meerhoff T.J., Kramarz P., Bonmarin I., Borgen K., Boucher C.A., et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill 2009, 14(46).
50. Kawai N., Ikematsu H., Iwaki N., Kondou K., Hirotsu N., Kawashima T., et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect 2009, 59(September (3)):207-212.
51. Kawai N., Ikematsu H., Hirotsu N., Maeda T., Kawashima T., Tanaka O., et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009, 49(December (12)):1828-1835.
52. Matsuzaki Y., Mizuta K., Aoki Y., Suto A., Abiko C., Sanjoh K., et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 2010, 7:53.
53. Saito R., Sato I., Suzuki Y., Baranovich T., Matsuda R., Ishitani N., et al. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A(H1N1) viruses with His275Tyr mutation. Pediatr Infect Dis J 2010, 29(10):898-904.
54. Dharan N.J., Gubareva L.V., Klimov A.I., Fiore A.E., Bresee J.S., Fry A.M. Antiviral treatment of patients with oseltamivir-resistant and oseltamivir-susceptible seasonal Influenza A (H1N1) infection during the 2007-2008 influenza season in the United States. Clin Infect Dis 2010, 50(February (4)):621-622.
55. van der Vries E., van den Berg B., Schutten M. Fatal oseltamivir-resistant influenza virus infection. New Engl J Med 2008, 359(September (10)):1074-1076.
56. Gooskens J., Jonges M., Claas E.C., Meijer A., van den Broek P.J., Kroes A.M. Morbidity and mortality associated with nosocomial transmission of oseltamivir-resistant influenza A(H1N1) virus. JAMA 2009, 301(March (10)):1042-1046.
57. Cowling B.J., Chan K.H., Fang V.J., Lau L.L., So H.C., Fung R.O., et al. Comparative epidemiology of pandemic and seasonal influenza A in households. New Engl J Med 2010, 362(June (23)):2175-2184.
58. Belongia E.A., Irving S.A., Waring S.C., Coleman L.A., Meece J.K., Vandermause M., et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 2010, 304(September (10)):1091-1098.
59. Shiley K.T., Nadolski G., Mickus T., Fishman N.O., Lautenbach E. Differences in the epidemiological characteristics and clinical outcomes of pandemic (H1N1) 2009 influenza, compared with seasonal influenza. Infect Control Hosp Epidemiol 2010, 31(July (7)):676-682.
60. CDC. Update: Influenza activity-United States, 2009-10 season. MMWR Morb Mortal Wkly Rep 2010;59(July (29)):8.
61. WHO. Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. Weekly Epidemiological Record on pandemic (H1N1) 2009. 2010 5th February 2010; 85(6):3.
62. Wolfe C., Greenwald I., Chen L. Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. Emerg Infect Dis 2010, 16(November (11)):1809-1811.
63. Nguyen H.T., Fry A.M., Loveless P.A., Klimov A.I., Gubareva L.V. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010, 51(October (8)):983-984.
64. van der Vries E., Stelma F.F., Boucher C.A. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. New Engl J Med 2010, 363(September (14)):1381-1382.
65. Barrero P.R., Viegas M., Valinotto L.E., Mistchenko A.S. Genetic and phylogenetic analyses of influenza A H1N1pdm virus in Buenos Aires, Argentina. J Virol 2010, 85(January (2)):1058-1066.
66. Graitcer S.B., Gubareva L., Kamimoto L., Doshi S., Vandermeer M., Louie J., et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 2011, 17(February (2)):255-257.
67. Speers D.J., Williams S.H., Pinder M., Moody H.R., Hurt A.C., Smith D.W. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust 2010, 192(February 3):166-168.
68. Alonso M., Rodriguez-Sanchez B., Giannella M., Catalan P., Gayoso J., Lopez Bernaldo de Quiros J.C., et al. Resistance and virulence mutations in patients with persistent infection by pandemic 2009 A/H1N1 influenza. J Clin Virol 2010, [November 10].
69. Hurt A.C., Deng Y.M., Ernest J., Caldwell N., Leang L., Iannello P., et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region March 2009 to March 2010. Euro Surveill 2011, 16(January (3)).
70. Lackenby A., Moran Gilad J., Pebody R., Miah S., Calatayud L., Bolotin S., et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus United Kingdom, winter 2010/11. Euro Surveill 2011, 16(5).
71. ECDC. Main surveillance developments in week 17/2011 (25 April-01 May 2011) Weekly influenza surveillance overview; 2011.
72. CDC. 2010-2011 Influenza Season Week 18 ending May 7, 2011. Weekly influenza surveillance report; 2011.
73. Renaud C., Boudreault A.A., Kuypers J., Lofy K.H., Corey L., Boeckh M.J., et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011, 17(April (4)):653-660.
74. Gooskens J., Jonges M., Claas E.C., Meijer A., Kroes A.C. Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009, 199(May (10)):1435-1441.
75. Boudreault A.A., Xie H., Leisenring W., Englund J., Corey L., Boeckh M. Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. Biol Blood Marrow Transplant 2010, [September 23].
76. Memoli M.J., Hrabal R.J., Hassantoufighi A., Eichelberger M.C., Taubenberger J.K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010, 50(9):4.
77. Tramontana A.R., George B., Hurt A.C., Doyle J.S., Langan K., Reid A.B., et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus Australia. Emerg Infect Dis 2010, 16(July (7)):1068-1075.
78. Harvala H., Gunson R., Simmonds P., Hardie A., Bennett S., Scott F., et al. The emergence of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus amongst hospitalised immunocompromised patients in Scotland November-December, 2009. Euro Surveill 2010, 15(14).
79. Anton A., Lopez-Iglesias A.A., Tortola T., Ruiz-Camps I., Abrisqueta P., Llopart L., et al. Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors. Diagn Microbiol Infect Dis 2010, 68(November (3)):214-219.
80. Campanini G., Piralla A., Rovida F., Puzelli S., Facchini M., Locatelli F., et al. First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection. J Clin Virol 2010, 48(July (3)):220-222.
81. Memoli M.J., Davis A.S., Proudfoot K., Chertow D.S., Hrabal R.J., Bristol T., et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis 2010, 203(February (3)):348-357.
82. Hamelin M.E., Baz M., Abed Y., Couture C., Joubert P., Beaulieu E., et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 2010, 6(7):e1001015.
83. Duan S., Boltz D.A., Seiler P., Li J., Bragstad K., Nielsen L.P., et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010, 6(7):e1001022.
84. Pizzorno A., Bouhy X., Abed Y., Boivin G. Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011, 203(January (1)):25-31.
85. Brookes D.W., Miah S., Lackenby A., Hartgroves L., Barclay W.S. Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. J Antimicrob Chemother 2010, [December 16].
86. Seibert C.W., Kaminski M., Philipp J., Rubbenstroth D., Albrecht R.A., Schwalm F., et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 2010, 84(November (21)):11219-11226.
87. Zonis Z., Engelhard D., Hindiyeh M., Ram D., Mandelboim M., Mendelson E., et al. Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel. Emerg Infect Dis 2010, 16(June (6)):1045-1046.
88. Moore C., Galiano M., Lackenby A., Abdelrahman T., Barnes R., Evans M.R., et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2010, 203(January (1)):18-24.
89. Le Q.M., Wertheim H.F., Tran N.D., van Doorn H.R., Nguyen T.H., Horby P. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. New Engl J Med 2010, 362(January (1)):86-87.
90. Ives J.A., Carr J.A., Mendel D.B., Tai C.Y., Lambkin R., Kelly L., et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antivir Res 2002, 55(August (2)):307-317.
91. Abed Y., Goyette N., Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 2004, 9(August (4)):577-581.
92. Herlocher M.L., Truscon R., Elias S., Yen H.L., Roberts N.A., Ohmit S.E., et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004, 190(November (9)):1627-1630.
93. Baz M., Abed Y., Simon P., Hamelin M.E., Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010, 201(March (5)):740-745.
94. Ottmann M., Duchamp M.B., Casalegno J.S., Frobert E., Moules V., Ferraris O., et al. Novel influenza A(H1N1) 2009 in vitro reassortant viruses with oseltamivir resistance. Antivir Ther 2010, 15(5):721-726.
95. Chan-Tack K.M., Murray J.S., Birnkrant D.B. Use of ribavirin to treat influenza. New Engl J Med 2009, 361(October (17)):1713-1714.
96. Wilson S.Z., Gilbert B.E., Quarles J.M., Knight V., McClung H.W., Moore R.V., et al. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother 1984, 26(August (2)):200-203.
97. CDC. Issues Interim Recommendations for the Use of Influenza Antiviral Medications in the Setting of Oseltamivir Resistance among Circulating Influenza A (H1N1) Viruses, 2008-09 Influenza Season. Available from: http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp%3FAlertNum=00279.
98. Dharan N.J., Beekmann S.E., Fiore A., Finelli L., Uyeki T.M., Polgreen P.M., et al. Influenza antiviral prescribing practices during the 2007-08 and 2008-09 influenza seasons in the setting of increased resistance to oseltamivir among circulating influenza viruses. Antivir Res 2010, 88(November (2)):182-186.
99. Kumar D., Morris M.I., Kotton C.N., Fischer S.A., Michaels M.G., Allen U., et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010, 10(January (1)):18-25.
100. Casper C., Englund J., Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010, 115(February (7)):1331-1342.
101. Nguyen J.T., Hoopes J.D., Smee D.F., Prichard M.N., Driebe E.M., Engelthaler D.M., et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009, 53(October (10)):4115-4126.
102. Nguyen J.T., Hoopes J.D., Le M.H., Smee D.F., Patick A.K., Faix D.J., et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5(2):e9332.
103. Tamura D., Sugaya N., Ozawa M., Takano R., Ichikawa M., Yamazaki M., et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011, 52(February (4)):432-437.
104. Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza. MMWR Morb Mortal Wkly Rep. 2011 January 21;60(1):1-25.
105. Ariano R.E., Sitar D.S., Zelenitsky S.A., Zarychanski R., Pisipati A., Ahern S., et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010, 182(March (4)):357-363.
106. Gaur A.H., Bagga B., Barman S., Hayden R., Lamptey A., Hoffman J.M., et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. New Engl J Med 2010, 362(January (1)):88-89.
107. Renaud C., Pergam S.A., Polyak C., Jain R., Kuypers J., Englund J.A., et al. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir. Transpl Infect Dis 2010, 12(6):513-517.
108. Dulek D.E., Williams J.V., Creech C.B., Schulert A.K., Frangoul H.A., Domm J., et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010, 50(June (11)):1493-1496.
109. Dohna-Schwake C., Schweiger B., Felderhoff-Muser U., Fiedler M., Kaiser G.M., Paul A., et al. Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications. Transplantation 2010, 90(July (2)):223-224.
110. Kidd I.M., Down J., Nastouli E., Shulman R., Grant P.R., Howell D.C.J., et al. H1N1 pneumonitis treated with intravenous zanamivir. The Lancet 2009, 374(9694):1036-1040.
111. Harter G., Zimmermann O., Maier L., Schubert A., Mertens T., Kern P., et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 2010, 50(May (9)):1249-1251.
112. Brown A.N., McSharry J.J., Weng Q., Adams J.R., Kulawy R., Drusano G.L. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrob Agents Chemother 2011, 55(April (4)):1740-1746.
113. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold?. Clin Infect Dis 2009, 48(January (Suppl 1)):S3-13.
114. Boltz D.A., Aldridge J.R., Webster R.G., Govorkova E.A. Drugs in development for influenza. Drugs 2010, 70(July (11)):1349-1362.